The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-β-cyclodextrin inclusion complexes. by Ye, YJ et al.
© 2015 Ye et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of Nanomedicine 2015:10 4309–4319
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
4309
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S83508
The preparation, characterization, and 
pharmacokinetic studies of chitosan nanoparticles 
loaded with paclitaxel/dimethyl-β-cyclodextrin 
inclusion complexes
Ya-Jing Ye1
Yun Wang1
Kai-Yan lou1
Yan-Zuo chen1
rongjun chen2
Feng gao1,3,4
1Department of Pharmaceutics, 
school of Pharmacy, east china 
University of science and Technology, 
shanghai, People’s republic of china; 
2Department of chemical engineering, 
Imperial college london, london, 
United Kingdom; 3shanghai Key 
laboratory of Functional Materials 
chemistry, 4shanghai Key laboratory 
of New Drug Design, east china 
University of science and Technology, 
shanghai, People’s republic of china
Abstract: A novel biocompatible and biodegradable drug-delivery nanoparticle (NP) has 
been developed to minimize the severe side effects of the poorly water-soluble anticancer drug 
paclitaxel (PTX) for clinical use. PTX was loaded into the hydrophobic cavity of a hydrophilic 
cyclodextrin derivative, heptakis (2,6-di-O-methyl)-β-cyclodextrin (DM-β-CD), using an 
aqueous solution-stirring method followed by lyophilization. The resulting PTX/DM-β-CD 
inclusion complex dramatically enhanced the solubility of PTX in water and was directly 
incorporated into chitosan (CS) to form NPs (with a size of 323.9–407.8 nm in diameter) using 
an ionic gelation method. The formed NPs had a zeta potential of +15.9–23.3 mV and showed 
high colloidal stability. With the same weight ratio of PTX to CS of 0.7, the loading efficiency 
of the PTX/DM-β-CD inclusion complex-loaded CS NPs was 30.3-fold higher than that of the 
PTX-loaded CS NPs. Moreover, it is notable that PTX was released from the DM-β-CD/CS 
NPs in a sustained-release manner. The pharmacokinetic studies revealed that, compared with 
reference formulation (Taxol®), the PTX/DM-β-CD inclusion complex-loaded CS NPs exhibited 
a significant increase in AUC
0→24h (the area under the plasma drug concentration–time curve 
over the period of 24 hours) and mean residence time by 2.7-fold and 1.4-fold, respectively. 
Therefore, the novel drug/DM-β-CD inclusion complex-loaded CS NPs have promising applica-
tions for the significantly improved delivery and controlled release of the poorly water-soluble 
drug PTX or its derivatives, thus possibly leading to enhanced therapeutic efficacy and less 
severe side effects.
Keywords: dimethyl-β-cyclodextrin, inclusion complex, chitosan nanoparticles, drug delivery, 
sustained release, paclitaxel
Introduction
Paclitaxel (PTX, molecular weight =853.91 g/mol, poorly water-soluble), a hydro-
phobic (HP) natural plant product, has shown potent antitumor effects against human 
solid tumors including breast cancer, ovarian cancer, and non-small cell lung cancer.1,2 
Usually, PTX is administered to patients via an intravenous route. Due to its low 
water solubility, some solubilizer or injection oil has to be used, which induces great 
toxicity such as hypersensitivity and peripheral neuropathy.3 The clinical use of PTX 
is impaired due to the lack of appropriate delivery vehicles. Therefore, there is a need 
for the development of a new formulation for the efficient loading, delivery, and sus-
tained release of the poorly water-soluble drug PTX in order to enhance its therapeutic 
efficacy and to minimize its side effects.
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Cyclodextrin (CD) has a hydrophilic outer surface and 
a HP central cavity. A variety of lipophilic drugs can be 
loaded into the HP cavity of CD via a HP interaction, thus 
improving the solubility of lipophilic drugs and the stability 
of labile drugs.4–6 It has been demonstrated that the use of 
β-CD can improve drug loading efficiency (LE), stabilize 
the incorporated drugs, and sustain the drug release of 
nanoparticles (NPs).7–10 Heptakis (2,6-di-O-methyl)-β-CD 
(DM-β-CD) is a derivative of β-CD, which not only has a 
suitable cavity depth and surface activity for drug loading 
but also shows 25 times higher water solubility than β-CD.11 
It was found that DM-β-CD had a dramatic improvement on 
the solubilization and stabilization of PTX.12,13
NP drug-delivery systems have been widely used to 
solubilize drugs, protect them from degradation, enhance 
their absorption and subsequent bioavailability, and modify 
their tissue distribution profiles.14,15 The biodegradable 
and biocompatible natural polymer chitosan (CS) has 
been extensively employed in the preparation of NPs. The 
mucoadhesive polymer can increase the residual time at 
the site of absorption, and has favorable controlled drug-
release abilities.15 Furthermore, it can be easily chemically 
crosslinked with multivalent anions such as the phosphate 
group of tripolyphosphate (TPP) via its ionic amino groups.16 
A number of research groups have reported the use of 
CS NPs for the delivery of poorly water-soluble drugs as 
well as water-soluble proteins.16–19 A recent tendency is to 
incorporate CD into CS NPs to further improve the stability 
and loading of poorly soluble drugs.20–22 These NPs have 
numerous features required for an ideal novel drug delivery 
system, such as uniform nanoscale size, biocompatible, 
biodegradable, stable, as well as high drug-loading and 
controlled-release capacities.23,24 It has become evident 
that these NPs could also load hydrophilic molecules with 
high efficiency and enhance their transport efficiency across 
mucosal surfaces.7,25 Here, CS, DM-β-CD, and PTX have 
been combined for the first time to construct a novel NP for 
the effective delivery of the clinically used, poorly water-
soluble anticancer drug PTX, and its potential to minimize 
the severe side effects of PTX has been investigated. PTX 
was complexed to DM-β-CD by an aqueous solution-stirring 
method and the resulting PTX/DM-β-CD inclusion complex 
was then incorporated into CS to form NPs by an ionic gela-
tion method for the first time. The physicochemical charac-
teristics of the NPs such as particle size, size distribution, 
entrapment efficiency (EE), LE, and in vitro drug release 
were determined. The pharmacokinetic parameters of these 
NPs were also investigated in rats.
Materials and methods
chemicals and reagents
CS (molecular weight =110 kDa, 90.0% deacetylation 
degree) was purchased from Yuhuan Ocean Biochemical 
Co. Ltd (Zhejiang, Peoples’ Republic of China). Heptakis 
DM-β-CD was purchased from Kaiyang Biotech Co. Ltd 
(Shanghai, Peoples’ Republic of China). Sodium TPP was 
purchased from the Shanghai Chemical Reagent Company 
(Shanghai, Peoples’ Republic of China). PTX (purity .99%) 
was purchased from Xi’an Qing Yue Biotechnology Co. Ltd 
(Xi’an, Peoples’ Republic of China). The male Wistar rats 
used in the experiments were supplied by the Department 
of Experimental Animals at Fudan University. All other 
reagents used in this study were high performance liquid 
chromatography (HPLC) or reagent grade.
Preparation of PTX/DM-β-cD inclusion 
complexes
The solid PTX/DM-β-CD inclusion complexes in a 
stoichiometric molar ratio ranging from 1:1 to 1:70 were 
prepared by an aqueous solution-stirring method and 
then dried by lyophilization.26 Typically, the calculated 
amounts of PTX and DM-β-CD were weighed and dis-
solved in 50% ethanol, which was mixed thoroughly under 
magnetic stirring for 24 hours at 20°C or 40°C. After 
equilibrium was reached, the mixture was evaporated. 
The PTX/DM-β-CD inclusion complexes were washed 
with ultrapure water several times and freeze dried. The 
yield of the inclusion complex was calculated according 
to Equation 1:
 Yield (%)
Weight of inclusion complexes
Weight of DM- -CD
weight o
= β +
f PTX
 
100%×  (1)
Preparation of cs NPs
CS NPs were prepared by a mild ionic crosslinking method 
according to the procedure previously developed by Yuan 
et al.19 Briefly, a CS solution (1 mg/mL) was prepared with 
glacial acetic acid, 1.75 times the CS weight. Then, the CS 
solution was adjusted to a pH of 3.8–6.5 with 0.1 N NaOH. 
The crosslinking agent TPP (1 mg/mL, 1 mL) was added 
dropwise to the CS solution with magnetic stirring at 800 rpm 
and continued stirring for a certain period of time (15, 30, 
60, or 120 minutes). The NPs were isolated from the solution 
by centrifugation for 30 minutes at 15,000 rpm and washed 
with water three times. The purified NPs were freeze dried 
to obtain dry NPs with 3% mannitol as a lyophilized protec-
tion agent. Each sample was prepared in triplicate to obtain 
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the average value of the obtained results and to calculate 
the error bars.
Preparation of DM-β-cD/cs NPs
DM-β-CD/CS NPs were prepared using the similar mild 
ionic crosslinking method as described above for prepar-
ing CS NPs. CS solution was adjusted to a pH of 4.5 with 
0.1 N NaOH, and the final concentration of CS solution 
was 1 mg/mL. One milliliter of 1 mg/mL TPP containing 
DM-β-CD (final concentration ranging from 0 to 30 mg/mL) 
was added dropwise to 5 mL of CS solution with magnetic 
stirring at 800 rpm and continued stirring for 30 minutes. 
The NPs were isolated from the solution by centrifugation 
and washed and freeze dried as described in the “Preparation 
of CS NPs” section.
Preparation of PTX-loaded cs NPs
PTX-loaded CS NPs were prepared using the similar 
crosslinking method as described above for preparing the 
CS NPs.19 CS solution was adjusted to the pH of 4.5 with 
0.1 N NaOH, and the final concentration of CS solution was 
1 mg/mL. The calculated amount of 2 mg/mL PTX in etha-
nol was added to 5 mL of CS solution at room temperature. 
The weight ratios of PTX to CS were 0, 0.7, and 1. PTX-
loaded CS NPs were formed by the continuous addition 
of 1 mg/mL TPP (1 mL) under stirring (800 rpm) at room 
temperature for 30 minutes. The NPs were washed and freeze 
dried as described in the “Preparation of DM-β-CD/CS 
NPs” section.
Preparation of PTX/DM-β-cD inclusion 
complex-loaded cs NPs
PTX/DM-β-CD inclusion complex-loaded CS NPs were pre-
pared using the similar crosslinking method as described for 
preparing the CS NPs. A certain amount of PTX/DM-β-CD 
inclusion complexes were dissolved in 5 mL of a 1 mg/mL 
CS solution. The pH of the CS solution was then adjusted to 
4.5 with 0.1 N NaOH. One milliliter of 1 mg/mL TPP was 
added dropwise to the CS solution with magnetic stirring at 
800 rpm for 30 minutes. The NPs were washed and freeze 
dried as described in the “Preparation of PTX-loaded CS 
NPs” section.
The physicochemical and morphological 
characterization of PTX/DM-β-cD 
inclusion complexes and NPs
The particle size and the zeta potential of the NPs in the 
aqueous solution were measured using Delsa Nano dynamic 
light scattering (DLS) (Beckman Coulter Inc, Brea, CA, 
USA) equipped with a 4 mW He-Ne laser at a wavelength 
of 633 nm at 25°C.
The Fourier transform infrared (FT-IR) spectra were 
recorded on a Nicolet 6700 FTIR spectrometer (Thermo 
Electron Scientific Instruments Corp, Madison, WI, USA) 
in the range of 4,000–400 cm-1 using KBr pellets.
The external morphology of PTX, DM-β-CD, and PTX/
DM-β-CD inclusion complex was analyzed by scanning 
electron microscopy. The samples were coated with platinum 
and observed with a scanning electron microscope (S-3400N, 
Hitachi, Tokyo, Japan). The morphological evaluation of NPs 
was performed with a JEM-2010 JEOL transmission electron 
microscope (TEM) (JASCO, Tokyo, Japan). Samples were 
stained with 2% (w/v) phosphotungstic acid and then dropped 
on a copper grid.
stability study
The CS NPs and DM-β-CD/CS NPs were freshly prepared, 
isolated and re-suspended in 0.9% (w/v) physiological saline. 
Samples were incubated at 4°C under agitation (100 rpm) and 
collected at different time points during a period of 35 days. 
The sizes of the NPs were measured by DLS. Each experi-
ment was performed in triplicate.
Determination of PTX by hPlc
PTX was determined using a modified reverse-phase HPLC 
system (Agilent Technologies, Santa Clara, CA, USA). 
Chromatographic separation was conducted on a Diamonsil® 
C18 column (4.6×250 mm, 5 µm, Dikma, Beijing, Peoples’ 
Republic of China). The ternary mobile phase consisted of 
methanol/acetonitrile/water (40/30/30, v/v/v), which was 
delivered at an isocratic flow rate of 1 mL/min at 40°C. 
The detection wavelength was set at 227 nm. The injec-
tion volume was 20 µL, and the retention time of PTX was 
9.5 minutes.
The entrapment and les of PTX/DM-β-
cD inclusion complexes and PTX-loaded 
NPs
For PTX/DM-β-CD inclusion complexes, a certain amount 
of inclusion complexes were solubilized with methanol and 
sonicated for 30 minutes. Then, the samples were diluted 
with methanol and the concentration of PTX was determined 
by HPLC.
For PTX-loaded NPs, the NPs were centrifuged and the 
supernatant was collected. The concentration of PTX in the 
supernatant was determined by HPLC.
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The EE and the LE were calculated as follows:
 EE (%)
(or inclusioncomplexes)
Tota
=
Amount of PTX in nanoparticles
l amount of PTX
00%×1  (2)
 LE (%)
Amount of PTX in nanoparticles
(or inclusion complexes)
Tot
=
al amount of nanoparticles
(or inclusion complexes)
100%×  (3)
The in vitro drug-release profiles  
of the NPs
The drug release from the PTX/DM-β-CD inclusion complex-
loaded CS NPs was investigated. The NPs (25 mg) and 2 mL 
of release medium were added to a dialysis tube, which was 
then placed in 50 mL of phosphate-buffered saline (PBS, 
pH 7.4) with continuous stirring at 100 rpm (37.0°C±0.5°C). 
At a specific time interval (5, 15, 30 minutes, 1, 2, 4, 8, 12, 
24, 36, and 48 hours), a 2 mL sample was collected from the 
bulk PBS solution and replaced by an equal volume of fresh 
PBS. The sample was filtered through a 0.22 µm filter unit 
and assayed using a UV spectrophotometer (Thermo Fisher, 
Waltham, MA, USA) at 227 nm. The accumulative release 
percentage was calculated at each time point. The analysis 
was performed in triplicate for each sample.
animal testing
Six male Wistar rats (250±15 g, fasting overnight) were 
randomly divided into two groups; Group A was treated 
with reference formulation (Taxol®) and Group B was treated 
with the PTX/DM-β-CD inclusion complex-loaded CS NPs. 
The reference formulation (Taxol®) and the PTX/DM-β-CD 
inclusion complex-loaded CS NPs were diluted in physi-
ological saline up to 0.5 mL and immediately injected into 
the tail vein of rats at a dose of 5 mg PTX/kg. Blood samples 
(0.2 mL) were drawn from the rat’s tail vein at specific time 
intervals and centrifuged to obtain plasma (100 µL). Methyl 
tert-butyl ether (1 mL) was added to the plasma and mixed 
for 3 minutes. The mixture was centrifuged at 12,000 rpm for 
5 minutes, and the upper part (0.9 mL) was transferred and 
dried by nitrogen gas. The residue was dissolved in 200 µL of 
the mobile phase, and the concentration of PTX in the plasma 
was assayed by HPLC. All of the animal experiments were 
carried out in accordance with the guidelines evaluated and 
approved by the ethics committee of East China University 
of Science and Technology.
statistical analysis
Multiple group comparisons were conducted using one-way 
analysis of variance and then by least significant difference 
using statistical software (SPSS, Chicago, IL, USA). All 
data are presented as a mean value with its standard devia-
tion (mean ± SD). P-values less than 0.05 were considered 
as statistically significant.
Results and discussion
PTX/DM-β-cD inclusion complexes
The PTX/DM-β-CD inclusion complex was prepared by an 
aqueous solution-stirring method. It was found that the molar 
ratio of PTX to DM-β-CD had a significant effect on the EE 
and the LE (Table 1). When the molar ratio was controlled 
as high as 1, the encapsulation of drugs into the HP cavity 
of DM-β-CD was not successful. Both the EE and the LE 
were significantly increased by decreasing the molar ratio 
down to 0.02 and then leveled off when the molar ratio was 
further decreased. This could be attributed to the relatively 
high molecular weight of PTX (853.906 g/mol) and its rela-
tively complex structure, leading to one PTX molecule not 
being able to be totally incorporated into one CD cavity. Two 
functional moieties of PTX have been reported to contribute 
Table 1 Physicochemical properties of the PTX/DM-β-cD inclusion complexes
Molar ratio of PTX to DM-β-CD Temperature (°C) EE (%) LE (%) Yield (%)
0.015 20 42.1±1.3 4.2±0.4 60.2±6.1
40 83.6±0.7 9.6±0.8 49.3±6.7
0.02 20 39.0±1.1 4.1±0.5 59.3±4.2
40 82.1±1.4 9.6±1.5 52.3±5.4
0.05 20 15.2±0.3 0.2±0.1 59.1±3.5
40 20.9±0.3 0.8±0.1 58.9±2.7
0.1 20 3.4±0.2 0.1±0.1 52.4±5.1
40 5.4±0.2 0.1±0.1 49.2±5.7
1 20 ND ND ND
Note: given values are means ± sD (n=3).
Abbreviations: DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; EE, entrapment efficiency; LE, loading efficiency; ND, no data; PTX, paclitaxel; SD, standard deviation.
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to its interaction with CD: one is the C-3′N benzoyl moiety 
(B-ring), and the other is a HP cluster site among the C-3′ 
phenyl (C-ring), C-2 benzoate (A-ring), and C-4 acetoxy 
moieties (Figure 1).27 These moieties may randomly enter the 
HP cavity of different CD molecules. In addition, the drug 
encapsulation can be further enhanced by increasing the tem-
perature from 20°C to 40°C. This might be due to the acceler-
ated molecular motion of PTX at higher temperatures, thus 
reducing the repulsive force between the hydrophilic groups 
on the surface of DM-β-CD and the HP groups of PTX. This, 
as a result, could facilitate the loading of the poorly water-
soluble PTX into the HP cavity of DM-β-CD.28 However, 
PTX might be decomposed after extended complexation with 
DM-β-CD at sufficiently high temperatures. The optimal 
PTX/DM-β-CD inclusion complexes, which were made at 
a temperature of 40°C and a complexation time of 24 hours, 
showed an EE of 82.1%±1.4% and an LE of 9.6%±1.5% and 
were used to prepare drug-delivery NPs.
Evidence for complexation formation of a guest molecule 
with CDs can be obtained by IR spectroscopy. A change in 
the characteristic absorption peaks of the guest molecule 
will be observed upon complexation. The IR spectra of PTX, 
DM-β-CD, PTX/DM-β-CD inclusion complex, and physi-
cal mixture of PTX and DM-β-CD are shown in Figure 2. 
IR spectrum of PTX (Figure 2A) showed absorption band at 
1,475 cm-1 that was assigned to benzene ring. IR spectrum 
of DM-β-CD (Figure 2B) showed characteristic absorption 
peaks of C-O-C and methyl group at 1,040 and 2,940 cm-1. IR 
spectrum of the physical mixture (Figure 2C) corresponded 
to the superposition of the spectra of the two individual 
components, and it retained the benzene ring absorption band 
of PTX at 1,475 cm-1. However, the benzene ring absorp-
tion band of PTX at 1,475 cm-1 was masked in the PTX/
DM-β-CD inclusion complex (Figure 2D). The -OH band 
at 3,400 cm-1 of PTX/DM-β-CD inclusion complex became 
broadened, suggesting the formation of hydrogen bonding 
between the drug and DM-β-CD. Moreover, the fingerprint 
spectra of physical mixture and PTX/DM-β-CD inclusion 
complex at 600–1,200 cm-1 were quite different. These 
observations led to the conclusion that the PTX/DM-β-CD 
inclusion complexes were successfully obtained.
The scanning electron microphotographs of PTX, 
DM-β-CD, and PTX/DM-β-CD inclusion complex are shown 
in Figure 3. PTX crystals appeared as aggregates of thin 
needles (Figure 3A),29 while DM-β-CD exhibited somewhat 
spherical shape with holes on the surface (Figure 3B).30 When 
PTX was incorporated into DM-β-CD, the resulting PTX/
DM-β-CD inclusion complex showed a drastic change in the 
shape and morphological features of the original PTX and 
DM-β-CD, which tended to be amorphous (Figure 3C). The 
change in the surface morphology of the inclusion complex 
was indicative of the presence of a new solid phase, which 
might be due to the molecular encapsulation of PTX in the 
DM-β-CD.
cs and DM-β-cD/cs NPs
CS NPs were prepared via the ionic crosslinking of CS with 
TPP, and the effects of the pH, the weight ratio of CS to TPP, 
and the crosslinking time on the particle size and zeta poten-
tial were investigated. As shown in Table 2, the solution pH 
played a critical role in the formation of CS NPs as CS is a 
weakly basic polysaccharide, with an average of 0.837 amino 
groups per disaccharide unit, and is insoluble at neutral or 
alkaline pH values. Precipitation of aggregates was observed 
at a pH of 6.5, which could be due to the reduced electrostatic 
repulsion between the formed NPs resulting from a low level 
of CS protonation. Upon further acidification to the pH range 
of 4.0–6.0, more amine groups of CS were positively charged. 
The resulting CS NPs showed the gradually increased zeta 
potential from 29.8 to 42.9 mV with a decreasing pH from 
6.0 to 4.0. The NPs had a typical hydrodynamic size ranging 
from 238.5 to 391.2 nm in diameter and displayed good col-
loidal stability. However, when the CS was further acidified 
to a pH of 3.8, no NPs were formed successfully. This is 
consistent with the argument that the formation of CS NPs 
and their surface charge densities are strongly dependent on 
the solution pH.31 Moreover, it was found that the formation 
of CS NPs was only possible for a certain weight ratio of 
CS to TPP within the range of 3–7. The smallest particle 
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Figure 1 chemical structure of paclitaxel with a numbering scheme.
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size was obtained at a weight ratio of 5 (ie, when the mole 
ratio of the CS unit to TPP was 9.9). Two CS units could be 
linked by one TPP molecule, which means that almost all of 
the amino groups of CS were involved in crosslinking and 
would result in more stable CS NPs. In addition, a marginal 
increase in particle size was observed when the crosslinking 
time was increased from 15 to 120 minutes.
DM-β-CD/CS NPs were prepared using the similar ionic 
crosslinking method and showed an increased hydrodynamic 
size and zeta potential compared with the control CS NPs 
(Table 3). The addition of smaller amounts of DM-β-CD 
(weight ratios of DM-β-CD to CS in the range of 0.5–1.5) 
resulted in the formation of larger particles, with diameters 
ranging from 440.2 to 521.4 nm. By increasing the weight 
ratio of DM-β-CD to CS further to the range of 2.0–6.0, 
the diameters of the NPs decreased to within the range of 
275.7–356.6 nm. The reason might be that low concentration 
of DM-β-CD could facilitate the incorporation process into 
CS and form larger particles, whereas high concentration 
of DM-β-CD might lead to a more compact and smaller 
nanostructure due to a series of weak intermolecular forces 
such as hydrogen bond/HP interactions between DM-β-CD 
and CS. The TEM image (Figure 4) showed the spherical 
morphology of the CS and DM-β-CD/CS NPs. Because of 
the presence of DM-β-CD, the size of the DM-β-CD/CS 
NPs had a minor increase compared with that of the CS 
NPs. However, no noticeable change in the appearance 
of the NPs was observed. The particle size determined by 
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Figure 2 Ir spectra of the (A) PTX, (B) DM-β-cD, (C) physical mixture of PTX and DM-β-cD, (D) PTX/DM-β-cD inclusion complex, (E) cs, (F) cs nanoparticles, and 
the (G) DM-β-cD/cs nanoparticles.
Abbreviations: cs, chitosan; DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; Ir, infrared; PTX, paclitaxel.
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A B
C
S-3400 15.0 kV 6.1 mm ×5.00 k SE 10.0 µm S-3400 15.0 kV 6.2 mm ×2.00 k SE 20.0 µm
S-3400 15.0 kV 5.5 mm ×2.00 k SE 20.0 µm
Figure 3 seM photographs of the (A) PTX, (B) DM-β-cD, and (C) PTX/DM-β-cD inclusion complex.
Abbreviations: DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; PTX, paclitaxel; seM, scanning electron microscopy.
Table 2 Physicochemical properties of the cs nanoparticles
pH Weight ratio  
of CS to TPP
Time  
(minutes)
Morphology Particle  
size (nm)
Zeta  
potential (mV)
PI
3.8 5 30 a ND ND ND
4.0 5 30 spherical 391.2±50.0 42.9±0.3 0.26
4.5 3 30 spherical 293.7±22.1 32.5±2.3 0.26
4.5 4 30 spherical 263.5±40.8 28.7±1.0 0.23
4.5 5 15 spherical 252.3±14.9 41.1±0.8 0.23
4.5 5 30 spherical 238.5±28.1 41.1±1.2 0.21
4.5 5 60 spherical 266.1±15.5 39.3±0.4 0.19
4.5 5 120 spherical 282.6±30.6 40.2±0.2 0.24
4.5 6 30 spherical 281.8±37.4 41.1±3.5 0.20
4.5 7 30 spherical 279.0±18.3 38.8±0.9 0.21
5.0 5 30 spherical 266.3±15.1 36.2±0.1 0.19
5.5 5 30 spherical 366.1±30.7 34.4±2.8 0.25
6.0 5 30 spherical 272.8±25.1 29.8±0.4 0.23
6.5 5 30 P ND ND ND
Notes: given values are means ± sD (n=3). The concentrations of cs and TPP were kept at 1.0 mg/ml.
Abbreviations: a, a clear solution was obtained; cs, chitosan; ND, no data; P, precipitation of aggregates was observed; PI, polydispersity index; sD, standard deviation; 
TPP, tripolyphosphate.
TEM in a dry state was smaller than the hydrodynamic size 
determined by DLS.
The structure, composition, and stability of the CS and 
DM-β-CD/CS NPs were investigated. Figure 2B, E, and F 
shows the FT-IR spectra of the DM-β-CD, CS, and CS 
NPs, respectively. The -OH stretching vibration shifted 
from 3,440 to 3,425 cm-1. The -NH
2
 bending vibration 
shifted from 1,620 to 1,545 cm-1, and a new peak appeared 
at 1,639 cm-1, indicative of the successful crosslinking inter-
action between TPP and the amino groups of CS within the 
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CS NPs (Figure 2F). Figure 2G shows the FT-IR spectrum 
of the DM-β-CD/CS NPs, which was similar to that of the 
CS NPs (Figure 2F) but distinct from that of the DM-β-CD 
(Figure 2B). The peak of 3,425 cm-1 became wider, indicat-
ing that hydrogen bonding was enhanced between CS and 
DM-β-CD.20 Figure 5 shows the time-dependent stability 
of the CS and DM-β-CD/CS NPs. No significant change in 
particle size was observed up to 35 days, indicating that both 
NPs were stable in 0.9% (w/v) physiological saline.
PTX-loaded cs NPs and PTX/DM-β-cD 
inclusion complex-loaded cs NPs
The PTX-loaded CS NPs and the PTX/DM-β-CD inclu-
sion complex-loaded CS NPs were prepared via the ionic 
crosslinking method, and the influence of the weight ratio 
of PTX to CS on their properties was investigated (Table 4). 
The hydrodynamic size of the NPs increased with the addi-
tion of PTX to CS. As shown in Table 4, the PTX-loaded 
CS NPs had low EEs (#9.13%) and low LEs (#0.15%) 
when the weight ratio of PTX to CS was in the range of 
0–1. PTX could not be efficiently incorporated into CS NPs 
due to the precipitation of the poorly water-soluble drugs 
in the CS solution. In the same range of the weight ratio 
of PTX to CS, PTX/DM-β-CD inclusion complex-loaded 
CS NPs exhibited significantly enhanced EEs and LEs up 
to 82.74% and 3.97%, respectively. With the same weight 
ratio of PTX to CS at 0.7, the LE of PTX/DM-β-CD inclu-
sion complex-loaded CS NPs was 30.3-fold higher than that 
of the PTX-loaded CS NPs. This is because HP PTX was 
efficiently loaded into the HP cavity of DM-β-CD, which 
has a hydrophilic outer surface and could be incorporated 
into the CS NPs easily, therefore leading to the significantly 
increased encapsulation of PTX into DM-β-CD/CS NPs. 
In the later study, the weight ratio of PTX to CS was set 
at 0.7 to prepare the PTX/DM-β-CD inclusion complex-
loaded CS NPs.
Table 3 Physicochemical properties of the DM-β-cD/cs nanoparticles
DM-β-CD (%, w/v) Weight ratio of DM-β-CD to CS Particle size (nm) Zeta potential (mV) PI
0 0 222.4±19.7 24.1±0.7 0.27
0.25 0.5 521.4±88.7 32.7±1.1 0.33
0.50 1.0 440.2±93.5 32.3±0.2 0.28
0.75 1.5 483.4±49.9 29.8±5.2 0.30
1.00 2.0 292.8±2.0 32.7±0.8 0.26
1.50 3.0 356.6±40.6 31.3±1.1 0.28
2.00 4.0 275.7±15.5 31.1±0.7 0.26
3.00 6.0 288.9±48.8 33.7±1.9 0.28
Notes: given values are means ± sD (n=3). Five milliliters of a 1 mg/ml chitosan solution were adjusted to a ph of 4.5. One milliliter of 1 mg/ml TPP containing DM-β-cD 
was added dropwise to the chitosan solution with magnetic stirring at 800 rpm and continued stirring for 30 minutes.
Abbreviations: cs, chitosan; DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; PI, polydispersity index; sD, standard deviation; TPP, tripolyphosphate.
50 nm 50 nm
A B
Figure 4 TeM photograph of the (A) cs and (B) DM-β-cD/cs nanoparticles.
Abbreviations: cs, chitosan; DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; TeM, transmission electron microscope.
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Figure 5 Time-dependent size change in cs nanoparticles (solid circles) and DM-
β-cD/cs nanoparticles (empty circles) following incubation in physiological saline 
(0.9% Nacl) at 4°c.
Note: The data are expressed as the mean ± sD (n=3).
Abbreviations: cs, chitosan; DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; NP, 
nanoparticle; sD, standard deviation.
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Figure 6 In vitro cumulative release of PTX from the PTX/DM-β-cD inclusion 
complex-loaded cs nanoparticles. The release medium was in PBs (ph 7.4).
Note: The data are expressed as the mean ± sD (n=3).
Abbreviations: cs, chitosan; DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; NP, 
nanoparticle; PBs, phosphate-buffered saline; PTX, paclitaxel; sD, standard 
deviation.
The in vitro drug-release profile of the PTX/DM-β-CD 
inclusion complex-loaded CS NPs was investigated in PBS 
(pH 7.4) at 37°C. As shown in Figure 6, free PTX in PBS solu-
tion was released rapidly from the dialysis tube and the cumula-
tive release reached 99.5% at 10 minutes. The PTX/DM-β-CD 
inclusion complex-loaded CS NPs displayed a sustained 
drug-release profile. It was a biphasic release process with an 
initial burst release phase followed by a delayed release phase. 
Compared with free PTX in PBS solution, the PTX/DM-β-CD 
inclusion complex-loaded CS NPs had a much smaller burst 
release with the cumulative release of PTX of 37.8% within 
the first 0.5 hour, which could be due to the desorption of the 
surface-bound or adsorbed drugs. In the delayed release phase, 
more drug was released from the incorporated PTX/DM-β-CD 
inclusion complexes or the inside of the NPs.
Pharmacokinetics in rats
The blood plasma concentration of PTX in rats was deter-
mined at various time points after the intravenous injection of 
a single dose of reference formulation (Taxol®) or the PTX/
DM-β-CD inclusion complex-loaded CS NPs (equivalent 
5 mg/kg PTX). As shown in Figure 7, the maximum plasma 
concentration of PTX after the intravenous administration of 
the PTX/DM-β-CD inclusion complex-loaded CS NPs was 
reached at 1 minute post-injection, and then a biphasic pro-
file with a rapid initial drug elimination phase was observed 
within the first 30 minutes, followed by a slower elimination 
phase. At 15 minutes post-injection, the blood plasma con-
centration of PTX in the rats treated with the PTX/DM-β-CD 
inclusion complex-loaded CS NPs was 18.1 µg/mL, while 
that in the rats treated with reference formulation (Taxol®) 
was only 7.5 µg/mL. In the extended post-injection period 
up to 24 hours, the PTX plasma concentration in the rats 
treated with the PTX/DM-β-CD inclusion complex-loaded 
CS NPs was 3.6-fold higher than that in the rats treated with 
reference formulation (Taxol®).
Table 4 Physicochemical properties of the PTX/DM-β-cD inclusion complex-loaded cs nanoparticles
PTX/DM-β-CD  
(mol/mol)
Weight ratio  
of PTX to CS
EE (%) LE (%) Particle  
size (nm)
Zeta  
potential (mV)
PI
1/0 0 ND ND 238.5±28.1 41.1±1.2 0.21
1/0 0.7 9.13±2.23 0.13±0.01 258.1±16.7 13.1±5.2 0.22
1/0 1 8.77±1.11 0.15±0.01 250.6±16.4 18.5±3.2 0.20
1/50 0.5 65.33±3.12 2.35±0.78 323.9±18.0 23.3±4.5 0.25
1/50 0.7 82.74±6.59 3.97±0.45 355.6±21.9 22.4±4.3 0.24
1/50 1 74.32±8.56 3.04±0.39 407.8±22.9 15.9±2.7 0.26
Notes: given values are means ± sD (n=3). Five milliliters of a 1 mg/ml chitosan solution were adjusted to a ph of 4.5. The calculated amount of 2 mg/ml PTX in ethanol 
was added to the chitosan solution at room temperature. Then, 1 mg/ml TPP (1 ml) was added dropwise to the chitosan solution with magnetic stirring at 800 rpm for 
30 minutes.
Abbreviations: cs, chitosan; DM-β-cD, (2,6-di-O-methyl)-β-cyclodextrin; EE, entrapment efficiency; LE, loading efficiency; ND, no data; PI, polydispersity index; PTX, 
paclitaxel; sD, standard deviation; TPP, tripolyphosphate.
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The pharmacokinetic parameters of reference formula-
tion (Taxol®) and the PTX/DM-β-CD inclusion complex-
loaded CS NPs in rats after intravenous administration 
are shown in Table 5. The PTX/DM-β-CD inclusion 
complex-loaded CS NPs showed an extended half-life 
of the elimination phase t
1/2β (6.10 hours) compared 
with reference formulation (Taxol®) (4.56 hours), while 
the elimination rate K
el
 constant of the NPs (0.54 h-1) 
was less than one-third that of reference formulation 
(Taxol®). This suggested that the clearance rate of PTX 
in the blood plasma decreased significantly when PTX 
was incorporated into the DM-β-CD/CS NPs. Moreover, 
the PTX/DM-β-CD inclusion complex-loaded CS NPs 
in rats showed a 2.7-fold increase in AUC
0→24h (the area 
under the plasma drug concentration–time curve over the 
period of 24 hours) and a 1.4-fold increase in the mean 
residence time compared with the reference formulation 
(Taxol®). The pharmacokinetic results showed that the 
PTX/DM-β-CD inclusion complex-loaded CS NPs could 
enable the drug payload to be released in a more stable 
and sustained manner.
Conclusion
The novel PTX/DM-β-CD inclusion complex-loaded CS 
NPs have been successfully prepared using biocompatible 
and biodegradable natural materials by an ionic gelation 
method. This work represented the first-known successful 
example of using DM-β-CD/CS as a carrier for the delivery 
of poorly water-soluble PTX. It was demonstrated in vitro 
that the drug-delivery system with a uniform particle size 
possessed a much higher drug encapsulation efficiency than 
PTX-loaded CS NPs and a lower burst release rate than 
reference formulation (Taxol®). The high AUC
0→24h value 
indicated that this nano-system had a sustained drug-release 
profile. Therefore, the DM-β-CD/CS NPs hold great poten-
tial as a biocompatible and biodegradable drug carrier for 
the significantly enhanced delivery and sustained release of 
poorly water-soluble drugs including PTX. This, as a result, 
would possibly enhance therapeutic efficacy and reduce the 
severe side effects of drugs.
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